RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Other Events
Item 8.01 Other Events.
On December 23, 2016 the Company issued a press release
announcing unblinded data, received from the University of
Illinois at Chicago, regarding the Phase 2B PACE (Pharmacotherapy
of Apnea by Cannabimimetic Enhancement) trial. That press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The PACE trial was conducted by the University of Illinois at
Chicago and Northwestern University. This was a six week,
placebo-controlled Phase 2B clinical trial investigating the
effects of dronabinol in patients with moderate to severe
obstructive sleep apnea. The Company has licensed from the
University of Illinois certain patent rights pertaining to the
use of cannabinoids, including dronabinol, for the treatment of
sleep-related breathing disorders such as obstructive sleep
apnea. The Company did not manage or fund this clinical trial,
which was fully funded by grant number 5UM1HL112856 from the
National Heart, Lung and Blood Institute of the National
Institutes of Health (NIH) and was managed by University of
Illinois at Chicago researchers.
On November 1, 2016, the Company filed a Current Report on Form
8-K attaching the Final Progress Report (the Project Report) to
the NIH, which contained blinded data for the PACE trial. The
Project Report indicated that the principal investigators
anticipated submitting an abstract for presentation at the
Sleep 2017 international conference of the Associated
Professional Sleep Societies, as well as a peer-review manuscript
detailing the findings in the winter of 2017.
The Company is providing the press release, to update investors
and shareholders with respect to the information available on
this Phase 2B clinical trial, which the Company has discussed in
its periodic filings with the Securities and Exchange Commission,
including its most recently filed Quarterly Report on Form 10-Q
for the quarterly period ended September 30, 2016, as amended.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of exhibits furnished as part of this report is set forth
in the Exhibit Index, which is presented elsewhere in this
document, and is incorporated herein by reference.
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea. RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Recent Trading Information
RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) closed its last trading session up +0.80 at 2.55 with 13,924 shares trading hands.
